- Home
- HMST vs MNPR Comparison
HMST vs MNPR Comparison
Compare HMST & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMST
- MNPR
- Stock Information
- Founded
- HMST 1921
- MNPR 2014
- Country
- HMST United States
- MNPR United States
- Employees
- HMST N/A
- MNPR N/A
- Industry
- HMST Major Banks
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- HMST Finance
- MNPR Health Care
- Exchange
- HMST Nasdaq
- MNPR Nasdaq
- Market Cap
- HMST 242.2M
- MNPR 248.8M
- IPO Year
- HMST 2012
- MNPR 2019
- Fundamental
- Price
- HMST $13.90
- MNPR $32.06
- Analyst Decision
- HMST Hold
- MNPR Strong Buy
- Analyst Count
- HMST 3
- MNPR 7
- Target Price
- HMST $14.17
- MNPR $62.00
- AVG Volume (30 Days)
- HMST 101.6K
- MNPR 29.7K
- Earning Date
- HMST 07-28-2025
- MNPR 08-12-2025
- Dividend Yield
- HMST N/A
- MNPR N/A
- EPS Growth
- HMST N/A
- MNPR N/A
- EPS
- HMST N/A
- MNPR N/A
- Revenue
- HMST $78,496,000.00
- MNPR N/A
- Revenue This Year
- HMST $161.80
- MNPR N/A
- Revenue Next Year
- HMST $8.90
- MNPR N/A
- P/E Ratio
- HMST N/A
- MNPR N/A
- Revenue Growth
- HMST N/A
- MNPR N/A
- 52 Week Low
- HMST $8.41
- MNPR $2.25
- 52 Week High
- HMST $16.10
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- HMST 63.61
- MNPR 37.84
- Support Level
- HMST $13.41
- MNPR $30.51
- Resistance Level
- HMST $13.99
- MNPR $37.56
- Average True Range (ATR)
- HMST 0.47
- MNPR 3.38
- MACD
- HMST 0.10
- MNPR -0.69
- Stochastic Oscillator
- HMST 67.31
- MNPR 12.93
About HMST HomeStreet Inc.
HomeStreet Inc is a commercial bank. It provides commercial loans and consumer loans including mortgage loans, deposit products, private banking, and cash management services. The company loan products include commercial business loans and agriculture loans, consumer loans, single family residential mortgages, loans secured by commercial real estate and construction loans for residential and commercial real estate projects.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.